Daiichi Sankyo
On May 7, 2008, Genta entered into a licensing agreement for global rights to tesetaxel with Daiichi Sankyo. Shortly thereafter, Genta secured FDA's agreement to remove the clinical hold with a brief submission that ensured patient safety.